Diabetic Neuropathy Market Size in the 7MM was ~USD 2,800 million which is expected to increase by 2034, estimates DelveInsight

DelveInsight's "Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Diabetic Neuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Diabetic Neuropathy Market is an evolving segment of the global healthcare landscape, driven by the increasing Diabetic Neuropathy prevalence of the disorder and the continuous development of innovative treatment options. The Diabetic Neuropathy market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Market with DelveInsight's In-Depth Report @ Diabetic Neuropathy Market Size [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Diabetic Neuropathy Market Report

* In November 2024:- Vertex Pharmaceuticals Incorporated- A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
* In November 2024:- MicuRx- A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI). This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
* In 2023, the total market size of diabetic neuropathy was around ~USD 2,800 million which is expected to increase by 2034 during the study period (2020-2034) in the 7MM.
* Among the 7MM, the United States accounted for the highest market size in 2023 followed by Germany for diabetic neuropathy.
* During the forecast period (2024-2034), pipeline candidates such as VM202 (donaperminogene seltoplasmid), VX-548, LX9211 and others, are expected to drive the rise in diabetic neuropathy market size.
* By 2034, LX9211 is expected to garner the largest market share in the 7MM.
* The leading Diabetic Neuropathic Pain companies such as AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Co, Eli Lilly, GlaxoSmithKline, Glenmark Pharmaceuticals, Grunenthal, Helixmith Co, Lexicon Pharmaceuticals, Mitsubishi Tanabe Pharma Corp, Mundipharma, Novaremed AG, Novartis, Ono Pharmaceutical, Centrexion Therapeutics, Pfizer, Regenacy Pharmaceuticals, Sun Pharmaceutical Industries, Cymbalta, UCB, Viatris and others.
* Promising Diabetic Neuropathic Pain Therapies such as Duloxetine, CNTX-6016, MEDI 7352, and others.

Stay ahead in the Diabetic Neuropathy Therapeutics Market with DelveInsight's Strategic Report @ Diabetic Neuropathy Market Outlook [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Neuropathy Epidemiology Segmentation in the 7MM

* Diabetic Neuropathy Prevalent Cases
* Diabetic Neuropathy Type-Specific Cases
* Diabetic Neuropathy Prevalent cases of painful and treated cases

Download the report to understand which factors are driving Diabetic Neuropathy epidemiology trends @ Diabetic Neuropathy Prevalence [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Neuropathy Marketed Therapies

* QUTENZA: Grunenthal and Averitas Pharma

QUTENZA (capsaicin) 8% topical system contains capsaicin in a localized dermal delivery system. The capsaicin in QUTENZA is a synthetic equivalent of the naturally occurring compound found in chili peppers. Capsaicin is soluble in alcohol, acetone, and ethyl acetate and very slightly soluble in water. QUTENZA is a single-use topical system stored in a foil pouch.

Capsaicin is an agonist for the transient receptor potential vanilloid I receptor (TRPV1), an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. This is followed by pain relief thought to be mediated by a reduction in TRPV1-expressing nociceptive nerve endings. Over several months, painful neuropathy may gradually re-emerge due to TRPV1 nerve fiber reinnervation of the treated area.

Diabetic Neuropathy Emerging Therapies

* ENGENSIS/VM202 (donaperminogene seltoplasmid): Helixmith

ENGENSIS/VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, nonviral, potentially regenerative plasmid DNA gene therapy. It is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms (HGF728 and HGF723) - a configuration that closely mimics HGF productions in humans that is needed for optimal therapeutic benefits (ViroMed, n.d.). As there is no change in the coding region of the HGF gene in VM202, the generated HGF proteins are identical to wild-type human HGF proteins. When introduced into the body through a simple series of intramuscular injections, HGF protein is expressed from VM202, induces the formation of new blood vessels (angiogenesis), suppresses levels of selected pain mediators (CSF-1, IL-6, 21, 5-HTT, and others), support regeneration/repair of damaged peripheral nerves, and ameliorates the atrophic condition of skeletal muscle.

* LX9211: Lexicon Pharmaceuticals

LX9211 is an orally-delivered small molecule compound Lexicon is developing to treat diabetic peripheral neuropathic pain. Lexicon's scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in their target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 and another development candidate were discovered by scientists working within the drug discovery alliance with Bristol Myers Squibb, from which the company holds exclusive development and commercialization rights.

Get In-Depth Knowledge on Diabetic Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Neuropathy Treatment Market [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Neuropathy Market Outlook

Due to a lack of treatments that target the underlying nerve damage, prevention is the key component of diabetes care. Screening for symptoms and signs of diabetic neuropathy is also critical in clinical practice, as it may detect the earliest stages of neuropathy, enabling early intervention. Prevention of diabetic neuropathy focuses primarily on glucose control and lifestyle modifications, which have the potential to prevent the disease or slow its progression.

The current modality of treatment largely focuses on the provision of symptomatic relief through pain management in diabetic peripheral neuropathy. Despite the major recent advances in elucidating the pathogenesis of diabetic neuropathy, there remains a lack of treatment options that effectively target the natural history of the disease or reverse it once established.

Scope of the Diabetic Neuropathy Market Report

* Coverage- 7MM
* Diabetic Neuropathic Pain Companies- AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Co, Eli Lilly, GlaxoSmithKline, Glenmark Pharmaceuticals, Grunenthal, Helixmith Co, Lexicon Pharmaceuticals, Mitsubishi Tanabe Pharma Corp, Mundipharma, Novaremed AG, Novartis, Ono Pharmaceutical, Centrexion Therapeutics, Pfizer, Regenacy Pharmaceuticals, Sun Pharmaceutical Industries, Cymbalta, UCB, Viatris and others.
* Diabetic Neuropathic Pain Therapies- Duloxetine, CNTX-6016, MEDI 7352, and others.
* Diabetic Neuropathy Market Dynamics: Diabetic Neuropathy Market Drivers and Barriers
* Diabetic Neuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Diabetic Neuropathy Market Report @ Diabetic Neuropathy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Diabetic Neuropathy Market Overview at a Glance

4. Executive Summary of Diabetic Neuropathy

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population of Diabetic Neuropathy in the 7MM

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Diabetic Neuropathy: 7MM Market Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-neuropathy-market-size-in-the-7mm-was-usd-2800-million-which-is-expected-to-increase-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.